Physician profile
David Palma
NPI 1578775854
$4,578.99
in general payments reported to CMS, 2019-2025
25 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $90.14 · 2021: $56.00 · 2022: $557 · 2023: $691 · 2024: $515 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Travel and Lodging: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.93 |
| Travel and Lodging | $1,500.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,745.95 | 2019-2025 | Overstitch Endoscopic Suturing System, Apollo Esg Nxt System |
| Abbvie INC. | $1,122.62 | 2019-2025 | |
| Endogastric Solutions, INC | $590.75 | 2019-2024 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.76 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $156.04 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $125.92 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $87.42 | 2019-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $75.02 | 2025 | Iqirvo |
| Pfizer INC. | $74.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $58.23 | 2022-2023 | Dificid |
| Medtronic, INC. | $44.78 | 2024-2025 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $35.62 | 2022 | |
| Daiichi Sankyo INC. | $35.54 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $33.68 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $32.01 | 2023 | Cimzia, Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $30.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.01 | 2025 | Dupixent |
| Ardelyx, INC. | $20.16 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $18.45 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.21 | 2023 | Cyltezo |
| Mylan Institutional INC. | $15.53 | 2023 | Hulio |
| Merit Medical Systems INC | $14.99 | 2025 | Esophyx |
| Aimmune Therapeutics, INC. | $13.72 | 2024 | |
| Phathom Pharmaceuticals, INC. | $12.17 | 2025 | Voquezna |
| Redhill Biopharma INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Palma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.